Abstract
Cladribine is a cytotoxic agent with high activity in hematological malignancies. It is usually administered intravenously. The study was carried out on 20 Egyptian hairy cell leukemia cases; 17 cases were de novo, and 3 cases were relapsed. Four (20%) were treated with IV cladribine, and 16 (80%) were treated with subcutaneous (SC) cladribine. An average duration of response was 36 months with no relapses in cases receiving IV cladribine vs. 25% relapse rate in cases receiving SC cladribine, with no significant difference between them. The subcutaneous administration of cladribine has a positive benefit/risk ratio in the treatment of patients with hairy cell leukemia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
